DE3249568C2 - - Google Patents

Info

Publication number: DE3249568C2
Authority: DE; Germany
Prior art keywords: lectin; cell membrane; gra; acetylgalactosamine; cancer
Prior art date: 1981-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

DE3249568A

Other languages

German (de)

English (en)

Other versions

DE3249568A1 (de

Inventor

Masakazu Takasaki Jp Adachi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Otsuka Pharmaceutical Co Ltd

Original Assignee

Otsuka Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-10-01

Filing date

1982-09-30

Publication date

1987-10-01

1981-10-01 Priority claimed from JP56156413A external-priority patent/JPS5857318A/ja

1981-10-01 Priority claimed from JP15641481A external-priority patent/JPS5857321A/ja

1981-10-05 Priority claimed from JP56158472A external-priority patent/JPS5859922A/ja

1981-10-05 Priority claimed from JP56158473A external-priority patent/JPS5859923A/ja

1982-06-28 Priority claimed from JP57111168A external-priority patent/JPS591420A/ja

1982-09-30 Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd

1985-02-07 Publication of DE3249568A1 publication Critical patent/DE3249568A1/de

1987-10-01 Application granted granted Critical

1987-10-01 Publication of DE3249568C2 publication Critical patent/DE3249568C2/de

Status Granted legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 claims description 44
201000011510 cancer Diseases 0.000 claims description 41
210000004027 cell Anatomy 0.000 claims description 39
108090001090 Lectins Proteins 0.000 claims description 33
102000004856 Lectins Human genes 0.000 claims description 33
239000002523 lectin Substances 0.000 claims description 33
238000000034 method Methods 0.000 claims description 22
239000000427 antigen Substances 0.000 claims description 16
102000036639 antigens Human genes 0.000 claims description 16
108091007433 antigens Proteins 0.000 claims description 16
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 15
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 14
108010046016 Peanut Agglutinin Proteins 0.000 claims description 10
210000000170 cell membrane Anatomy 0.000 claims description 10
229930182830 galactose Natural products 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
102000007563 Galectins Human genes 0.000 claims description 5
108010046569 Galectins Proteins 0.000 claims description 5
238000000265 homogenisation Methods 0.000 claims description 3
238000005063 solubilization Methods 0.000 claims description 3
230000007928 solubilization Effects 0.000 claims description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
239000012528 membrane Substances 0.000 claims 2
101710186708 Agglutinin Proteins 0.000 claims 1
239000004471 Glycine Substances 0.000 claims 1
101710146024 Horcolin Proteins 0.000 claims 1
244000112675 Lablab purpureus Species 0.000 claims 1
101710189395 Lectin Proteins 0.000 claims 1
101710179758 Mannose-specific lectin Proteins 0.000 claims 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 claims 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 claims 1
239000000910 agglutinin Substances 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
238000004140 cleaning Methods 0.000 claims 1
239000000872 buffer Substances 0.000 description 23
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
229920002684 Sepharose Polymers 0.000 description 12
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 11
239000001110 calcium chloride Substances 0.000 description 11
235000011148 calcium chloride Nutrition 0.000 description 11
229910001628 calcium chloride Inorganic materials 0.000 description 11
229910001629 magnesium chloride Inorganic materials 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
229920004890 Triton X-100 Polymers 0.000 description 9
239000000243 solution Substances 0.000 description 9
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
238000001042 affinity chromatography Methods 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
238000000926 separation method Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 5
108010039433 dolichos biflorus agglutinin Proteins 0.000 description 5
239000000126 substance Substances 0.000 description 5
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
229940041181 antineoplastic drug Drugs 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
-1 bromoacetyl Chemical group 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920001542 oligosaccharide Chemical group 0.000 description 2
150000002482 oligosaccharides Chemical group 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000002308 calcification Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
108010065337 fluorescein isothiocyanate-peanut agglutinin Proteins 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

DE19823249568 1981-10-01 1982-09-30 Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs Granted DE3249568A1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP56156413A JPS5857318A (ja)	1981-10-01	1981-10-01	癌細胞障害性リンパ球の製造法
JP15641481A JPS5857321A (ja)	1981-10-01	1981-10-01	抗癌剤
JP56158472A JPS5859922A (ja)	1981-10-05	1981-10-05	癌細胞障害性リンパ球
JP56158473A JPS5859923A (ja)	1981-10-05	1981-10-05	抗癌剤
JP57111168A JPS591420A (ja)	1982-06-28	1982-06-28	糖鎖関連抗原およびその製造法

Publications (2)

Publication Number	Publication Date
DE3249568A1 DE3249568A1 (de)	1985-02-07
DE3249568C2 true DE3249568C2 (fr)	1987-10-01

Family

ID=27526479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE19823249568 Granted DE3249568A1 (de)	1981-10-01	1982-09-30	Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs
DE19823236298 Granted DE3236298A1 (de)	1981-10-01	1982-09-30	Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE19823236298 Granted DE3236298A1 (de)	1981-10-01	1982-09-30	Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten

Country Status (19)

Country	Link
AR (1)	AR230731A1 (fr)
AT (2)	AT382080B (fr)
AU (1)	AU554858B2 (fr)
BE (1)	BE893704A (fr)
CA (1)	CA1195269A (fr)
CH (2)	CH655661B (fr)
DD (2)	DD209577A5 (fr)
DE (2)	DE3249568A1 (fr)
DK (1)	DK292182A (fr)
FI (1)	FI77157C (fr)
FR (1)	FR2513882B1 (fr)
IL (1)	IL66270A (fr)
IT (1)	IT1189305B (fr)
MX (1)	MX7437E (fr)
NL (1)	NL8202638A (fr)
NO (1)	NO161601C (fr)
NZ (1)	NZ201112A (fr)
PT (1)	PT75148B (fr)
SE (1)	SE8204058L (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60214737A (ja) *	1984-04-06	1985-10-28	Nippon Koutai Kenkyusho:Kk	糖鎖関連抗原の製造法
EP0334300A1 (fr) *	1988-03-21	1989-09-27	Neorx Corporation	Utilisation d'anticorps monoclonaux et de conjugués de ceux-ci comme signaux pour diriger des cellules effecteurs sensibilisées sur des lieux tumoraux

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1193378A (en) *	1967-04-11	1970-05-28	Rand Dev Corp	Cancer Antigen Complexes
DE1943699A1 (de) *	1969-08-28	1971-03-04	Stiftung Onophrio	Heilmittel mit proliferationshemmender Wirkung und Verfahren zur Herstellung dieses Heilmittels
YU34005B (en) *	1970-02-24	1978-10-31	Podvinec Srecko	Process for obtaining bovine lymphatic gland extract
US4371515A (en) *	1978-12-26	1983-02-01	E-Y Laboratories, Inc.	Method for forming an isolated lectin-immunological conjugate

1982
- 1982-06-29 NZ NZ201112A patent/NZ201112A/en unknown
- 1982-06-29 FI FI822325A patent/FI77157C/fi not_active IP Right Cessation
- 1982-06-29 DK DK292182A patent/DK292182A/da not_active Application Discontinuation
- 1982-06-29 NO NO822215A patent/NO161601C/no unknown
- 1982-06-29 PT PT75148A patent/PT75148B/pt not_active IP Right Cessation
- 1982-06-30 CH CH551284A patent/CH655661B/de unknown
- 1982-06-30 DD DD82241290A patent/DD209577A5/de not_active IP Right Cessation
- 1982-06-30 SE SE8204058A patent/SE8204058L/xx not_active Application Discontinuation
- 1982-06-30 MX MX8210163U patent/MX7437E/es unknown
- 1982-06-30 FR FR8211489A patent/FR2513882B1/fr not_active Expired
- 1982-06-30 DD DD82261475A patent/DD221917A5/de not_active IP Right Cessation
- 1982-06-30 AR AR289864A patent/AR230731A1/es active
- 1982-06-30 IT IT48724/82A patent/IT1189305B/it active
- 1982-06-30 BE BE0/208493A patent/BE893704A/fr not_active IP Right Cessation
- 1982-06-30 CH CH398882A patent/CH655660B/de unknown
- 1982-06-30 AU AU85458/82A patent/AU554858B2/en not_active Ceased
- 1982-06-30 NL NL8202638A patent/NL8202638A/nl not_active Application Discontinuation
- 1982-07-08 IL IL66270A patent/IL66270A/xx unknown
- 1982-09-30 DE DE19823249568 patent/DE3249568A1/de active Granted
- 1982-09-30 DE DE19823236298 patent/DE3236298A1/de active Granted
- 1982-10-01 CA CA000412670A patent/CA1195269A/fr not_active Expired
- 1982-10-01 AT AT0363782A patent/AT382080B/de not_active IP Right Cessation
1985
- 1985-12-09 AT AT0354585A patent/AT390002B/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ201112A (en)	1986-10-08
MX7437E (es)	1988-11-14
SE8204058D0 (sv)	1982-06-30
DD209577A5 (de)	1984-05-16
PT75148B (en)	1986-08-14
FI77157B (fi)	1988-10-31
FR2513882B1 (fr)	1986-04-04
DD221917A5 (de)	1985-05-08
AU554858B2 (en)	1986-09-04
FR2513882A1 (fr)	1983-04-08
IT8248724A0 (it)	1982-06-30
IL66270A (en)	1986-03-31
AT382080B (de)	1987-01-12
DE3236298A1 (de)	1984-03-15
CH655660B (fr)	1986-05-15
FI77157C (fi)	1989-02-10
ATA363782A (de)	1986-06-15
AU8545882A (en)	1983-04-14
BE893704A (fr)	1982-10-18
NO161601B (no)	1989-05-29
DE3249568A1 (de)	1985-02-07
PT75148A (en)	1982-07-01
IL66270A0 (en)	1982-11-30
CA1195269A (fr)	1985-10-15
DE3236298C2 (fr)	1987-09-24
AT390002B (de)	1990-03-12
ATA354585A (de)	1989-08-15
IT1189305B (it)	1988-02-04
NO161601C (no)	1989-09-06
AR230731A1 (es)	1984-06-29
CH655661B (fr)	1986-05-15
DK292182A (da)	1983-04-02
NL8202638A (nl)	1983-05-02
FI822325A0 (fi)	1982-06-29
SE8204058L (sv)	1983-04-02
NO822215L (no)	1983-04-05
FI822325L (fi)	1983-04-02

Legal Events

Date	Code	Title	Description
1985-02-07	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1985-02-07	OP8	Request for examination as to paragraph 44 patent law
1987-09-24	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1987-10-01	AC	Divided out of	Ref country code: DE Ref document number: 3236298 Format of ref document f/p: P
1987-10-01	D2	Grant after examination
1988-03-31	8364	No opposition during term of opposition
1992-09-10	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE3227262C3 (de)	1996-03-21	Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor
DE3686927T2 (de)	1993-03-25	Neovaskularisierungsinhibitoren und deren herstellung.
EP0225496B1 (fr)	1992-05-20	Polysaccharides immunostimulantes à partir de cultures de cellules d'Echinacea purpurea (Linné) Moench et d'Echinacea angustifolia (De Vandolle), leur procédé de préparation et compositions pharmaceutiques les contenant
DE2638762A1 (de)	1977-03-10	Wasserloesliche adjuvantien, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3149360A1 (de)	1983-06-16	"verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
DE68922109T2 (de)	1995-10-12	Gamma-inulin-zusammensetzungen.
DE69014543T2 (de)	1995-06-22	Multivalentes immunogen lmi.
CH628246A5 (de)	1982-02-26	Verfahren zur herstellung eines schuetzenden pertussis-antigens.
DE3012204A1 (de)	1980-10-23	Antigen, verfahren zu seiner herstellung und seine verwendung
DE3249568C2 (fr)	1987-10-01
EP0287076A1 (fr)	1988-10-19	Récepteur du groupe récepteur mineur de rhinovirus
DE60022499T2 (de)	2006-11-30	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
EP0395851B1 (fr)	1996-06-26	Glycoprotéines d'Avena sativa procédé pour les obtenir et leur utilisation comme médicaments
EP0445710A1 (fr)	1991-09-11	Utilisation d'hydroxides zinc-calcium, de la lecithine et de PAOs pour adjuver des solutions d'antigens et solutions d'antigens ainsi adjuvées
DE69532557T2 (de)	2004-12-23	Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene
DE60024969T2 (de)	2006-09-07	2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
DE2513848A1 (de)	1975-10-09	Verfahren zur gewinnung ununterbrochener staemme von tumorzellen in vitro
JPS5857321A (ja)	1983-04-05	抗癌剤
DE2646223C2 (fr)	1990-09-27
US7604824B2 (en)	2009-10-20	Method for extraction lectin from Chaenomeles lagenaria, medical composition for inhibiting tumor growth, biological reagent for detecting glycophorin A on blood and blood typing kit
DE3850692T2 (de)	1995-02-02	Treponema hyodysenteriae-Antigen und seine Verwendungen.
DE60223232T2 (de)	2008-08-14	Mucinpeptid mit immunstärkenden eigenschaften
JPS63164895A (ja)	1988-07-08	培養細胞由来のレクチン様蛋白質及びその製法並びに該物質を主成分とする抗腫瘍剤
DE69932711T2 (de)	2007-08-16	Proteine mit modulatorischer aktivität gegenüber dem immunsystem und behandlungen für immunologische erkrankungen
DE2016274A1 (fr)	1970-10-22